ChemicalBook
English   Japanese   Germany   Korea

PNU159682

PNU159682, 202350-68-3, 结构式
PNU159682
CAS号:
202350-68-3
英文名:
PNU-159682
英文别名:
PNU-159682;PNU-159682 95%;PNU-159682 >95%; 5-hydroxy-6-tert.-butyl-1,1-pentamethylene-3,3-dimethyl-indane;inhibit,non-Hodgkin’s lymphoma,PNU159682,ADCs Toxin,PNU-159682,acute myeloid leukemia,ADC Payload,EDV nanocell,AML,Inhibitor,ADC Cytotoxin,PNU 159682,Topoisomerase,NMS249,NHL;(8S,10S)-6,8,11-Trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-7,8,9,10-tetrahydrotetracene-5,12-dione;(8S,10S)-6,8,11-Trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-7,8,9,10-tetrahydrotetracene-5,12-dione;(8S,10S)-7,8,9,10-Tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[(1S,3R,4aS,9S,9aR,10aS)-octahydro-9-methoxy-1-methyl-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl]oxy]-5,12-naphthacenedione;5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[(1S,3R,4aS,9S,9aR,10aS)-octahydro-9-methoxy-1-methyl-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl]oxy]-, (8S,10S)-
中文名:
PNU159682
中文别名:
蒽环类新霉素;化合物PNU-159682;拓扑异构酶抑制剂(PNU-159682);(8S,10S)-6,8,11-三羟基-8-(2-羟基乙酰基)-1-甲氧基-10-(((1S,3R,4AS,9S,9AR,10AS)-9-甲氧基-1-甲基八氢-1H-吡喃并[4',3':4,5]恶唑并[2,3-C][1,4]恶嗪-3-基)氧基)-7,8,9,10-四氢并四苯-5,12-二酮;(8S,10S)-6,8,11-三羟基-8-(2-羟基乙酰基)-1-甲氧基-10-(((1S,3R,4AS,9S,9AR,10AS)-9-甲氧基-1-甲基八氢-1H-吡喃并[4',3':4,5]恶唑并[2,3-C][1,4]恶嗪-3-基)氧基)-7,8,9,10-四氢并四苯-5,12-二酮;(8S,10S)-7,8,9,10-四氢-6,8,11-三羟基-8-(2-羟基乙酰基)-1-甲氧基-10-[[(1S,3R,4AS,9S,9AR,10AS)-八氢-9-甲氧基-1-甲基-1H-吡喃并[4',3':4,5]恶唑并[2,3-C][1,4]恶嗪-3-基]氧基] - 5,12-萘二酮
CBNumber:
CB12702958
分子式:
C32H35NO13
分子量:
641.62
MOL File:
202350-68-3.mol

PNU159682化学性质

沸点:
838.5±65.0 °C(Predicted)
密度:
1.58±0.1 g/cm3(Predicted)
储存条件:
under inert gas (nitrogen or Argon) at 2–8 °C
酸度系数(pKa):
7.34±0.60(Predicted)
安全信息

PNU159682性质、用途与生产工艺

生物活性

PNU-159682 是蒽环类新霉素代谢产物的代谢产物,是一种 DNA 拓扑异构酶 I (Topo I) 抑制剂,具有出色的细胞毒性。在ADC 合成中,PNU-159682 是一种比阿霉素更有效和耐受性更高的 ADC 细胞毒素 (ADC cytotoxin)。PNU-159682 可用于 EDV 纳米细胞技术,克服耐药性。

靶点

Daunorubicins/Doxorubicins

Topoisomerase I

体外研究

PNU-159682 (0-500 nM; exposed to the compounds for 1 hour and then cultured in compound-free medium for 72 hours) has cytotoxic effects on human tumor cell lines in a sulforhodamine B assay. The IC 70 values are 0.577 nM, 0.39 nM, 0.128 nM, and 0.081 nM, 0.086 nM and 0.075 nM for HT-29, A2780, DU145, EM-2, Jurkat and CEM cells, respectively. It against human tumor cell lines with IC 70 in the ranging 68 nM-578 nM and 181 nM-1717 nM towards MMDX and doxorubicin, respectively. PNU-159682 is more potent than MMAE on NHL cell lines. In a cell viability assay, PNU-159682 is against BJAB.Luc, Granta-519, SuDHL4.Luc, and WSU-DLCL2 with IC 50 values of 0.10 nM, 0.020 nM, 0.055 nM, and 0.1 nM, respectively. While MMAE is against BJAB.Luc, Granta-519, SuDHL4.Luc, and WSU-DLCL2 with IC 50 values of 0.54 nM, 0.25 nM, 1.19 nM and 0.25 nM, respectively.PNU-159682 is thousands of times more cytotoxic than doxorubicin and can be used to develop a new class of ADCs. PNU159682 to anti-CD22 antibody (anti-CD22-NMS249) exhibits strong anti-tumor effects in vitro . Anti-CD22-NMS249 (PNU159682 to anti-CD22 antibody) is active in in vitro viability assays of NHL cell lines and is 2 to 20 fold more potent than pinatuzumab vedotin, the ADC anti-CD22-NMS249 is against BJAB.Luc, Granta-519, SuDHL4.Luc, and WSU-DLCL2 with IC 50 values of 0.058 nM, 0.030 nM, 0.0221 nM, and 0.01 nM, respectively.PNU-159682 (100 μM) weakly inhibits topoisomerase II unknotting activity. PNU-159682 shows cytotoxic effect on CAIX-expressing SKRC-52 cells with IC 50 of 25 nM.

Cell Viability Assay

Cell Line: HT-29, A2780, DU145, EM-2, Jurkat and CEM cells
Concentration: 0-500 nM
Incubation Time: Exposed to the PNU-159682 for 1 hour and then cultured in compound-free medium for 72 hours
Result: Was 2,360- to 790-fold and 6,420- to 2,100-fold more potent than MMDX and doxorubicin, respectively. Exhibited IC 70 values of PNU-159682 are in the subnanomolar range (0.07-0.58 nM) and noticeably lower than that recorded for both MMDX and doxorubicin.

体内研究

PNU-159682 (single-dose; i.v.15 μg/kg) is a maximum tolerated dose in murine L1210 leukemia model. PNU-159682 shows an improved antitumor activity in vivo. The antitumor effect of PNU-159682 (increase in life span=29%) is comparable to that afforded by 90 μg/kg MMDX (increase in life=36%).PNU-159682 (i.v. 4 μg/kg; q7dx3; 40 days) has a therapeutic response in MX-1 human mammary carcinoma mice. What’s more, from day 39, four out of seven mice receiving PNU-159682 exhibits complete tumor regression.PNU-159682 is more cytotoxic than doxorubicin and can be used to develop a new class of ADCs. PNU159682 to anti-CD22 antibody (anti-CD22-NMS249) exhibits strong anti-tumor effects in vivo . ADC dose (anti-CD22-NMS249; 50 µg/m2 conjugated PNU-159682) is well tolerated in mice and results in less than 10% weight loss.In the BJAB.Luc model the efficacy of antiCD22-NMS249 (single dose; 2 mg/kg) is similar to anti-CD22-vc-MMAE. At 2 mg/kg dosage, antiCD22-NMS249 gives complete remission of the tumors (NMS249: 110-134%TGI vs. vc-MMAE: 114-143%TGI). Additionally, a single dose of antiCD22-NMS249 at 2 mg/kg results in tumor stasis for three weeks.

Animal Model: Four- to six-week-old female CD-1 athymic nude mice with MX-1 tumor fragments
Dosage: 4 μg/kg
Administration: Intravenous injection; q7dx3; 40 days
Result: Exhibited anti-cancer effects in MX-1 human mammary carcinoma xenografts to PNU-159682.

PNU159682 上下游产品信息

上游原料

下游产品

PNU159682 试剂级价格

更新日期产品编号产品名称CAS编号包装价格
2024/04/30HY-16700PNU-1596821 mg1500元
2024/04/30HY-16700PNU159682
PNU-159682
202350-68-35mg3750元

PNU159682 生产厂家

全球有 72家供应商   PNU159682国内生产厂家
供应商联系电话电子邮件国家产品数优势度
戊言医药科技(上海)有限公司 021-61001086 13671938079 sales@wuyanpharm.com 中国 99 55
联宁(苏州)生物制药有限公司 0512-81877925 051281877925 info@levena.cn 中国 48 58
上海瑞昶医药科技有限公司 18621054990 maychemicals@sina.com 中国 675 58
武汉多普乐生物医药有限公司 +86-02787215551 +86-19945035818 2936752263@qq.com 中国 7954 58
武汉英诺医药科技有限公司 +86-027-59232304 15387063101 2881924050@qq.com 中国 9991 58
武汉沃格达生物科技有限公司 15071299552 262933239@qq.com 中国 6637 58
合肥恩立医药科技有限公司 0551-66399836 18955197623 sales@enlipharma.com 中国 1874 55
上海波以尔化工有限公司 sales@boylechem.com 中国 2923 55
上海佰世凯化学科技有限公司 021-20908456 sales@BioChemBest.com 中国 6011 61
上海皓元医药股份有限公司 021-58950125 info@chemexpress.com 中国 7553 61
MedChemexpress LLC 021-58955995 sales@medchemexpress.cn 美国 4863 58
南京联宁生物制药有限公司 025-58073912 1482480248 service@levena.cn 中国 6 58
上海楼岚生物科技有限公司 021-52996696,15000506266 15000506266 中国 4121 55
广州致雅医药科技有限公司 18122150900 sculk28@163.com 中国 647 55
斯派螺(武汉)药物研发有限公司 eric_feng1954@126.com 中国 9254 55
BOC Sciences 16314854226 info@bocsci.com 美国 9926 65
上海昂提生物科技有限公司 13764913901 info@angtibio.com 中国 4493 55
上海昶衍化工科技有限公司 021-021-20242659 18930833303 order@changyanchem.com 中国 5008 55
上海瀚香生物科技有限公司 17754423994 17754423994 2853530910@QQ.com 中国 7998 62
上海芮晖化工科技有限公司 21-31433387 15618786686 sales@rechemscience.com 中国 2985 58
北京普西唐生物科技有限公司 010-60605840 18892239720 psaitong@jm-bio.com 中国 12308 58
常州美泰生物科技有限公司 0519-83246372 13585352506 中国 1844 58
威尔曼医药集团有限公司 027-027-83778875 15807197853 15807197853@163.com 中国 3979 58
凯立德生物医药技术(上海)有限公司 021-58180488 sales@MedChemLeader.com 中国 999 58
上海珀法姆医药科技有限公司 +86 18721201413 sales@biopharmaleader.com 中国 1720 58
苏州爱玛特生物科技有限公司 0512-56316828 info@amateksci.com 中国 28822 58
Musechem +1-800-259-7612 info@musechem.com 美国 4662 60
上海与昂生物科技有限公司 021-58111628 15800915896 中国 1988 58
南京安美科技有限公司 025-84767922 18936879710 sales@abydoscientific.com 中国 1029 58
范德(北京)生物科技有限责任公司 15911056312 liming@bio-fount.com 中国 9730 58
InvivoChem +1-708-310-1919 +1-13798911105 sales@invivochem.cn 美国 6393 58
上海源溪生物科技有限公司 021-58447131 13564518121 sales@dcchemicals.com 中国 9414 58
常州辰鸿生物科技有限公司 0519-85788828 13775037613 sales@chemrenpharm.com 中国 3553 58
无锡科华生物科技有限公司 0510-0510-86838766 2258830676@qq.com 中国 3825 58
BOC Sciences +1-631-485-4226 inquiry@bocsci.com 美国 19553 58
上海皓元医药股份有限公司 021-58950125 info@chemexpress.com 中国 691 58
河南科锐化工有限公司 +86-0371-86658258 15093356674 factory@coreychem.com 中国 29826 58
上海泽叶生物科技有限公司 021-61998551 13122364865 sale1@shzysw.net 中国 9763 58
爱必信(上海)生物科技有限公司 021-38015121 15000105423 chenjw@absin.cn 中国 24734 58
上海弘渠生物医药科技有限公司 88888888888 hongquchem@qq.com 中国 5132 58
学研惠(武汉)科技有限公司 15342225168 yutianchun2007@126.com 中国 9990 58
深圳市凯米克生物科技有限公司 18964309092 18964309092 2769493375@qq.com 中国 2635 58
天津普西唐生物医药科技有限公司 010-60605840 psaitong@jm-bio.com 中国 29778 58
湖北科乐精细化工有限公司 027-59101668 19945030958 2881924765@qq.com 中国 7980 58
镇江仁志生物技术有限公司 18762678737 751546636@qq.com 中国 62 58
湖北魏氏化学试剂股份有限公司 186-27096350 18627096350 2853877630@qq.com 中国 2626 58
ChemeGen 中国 18818260767 sales@chemegen.com 中国 6975 58
广东翁江化学试剂有限公司 0751-2815987 13927875076 3007432263@qq.com 中国 9979 58
上海毕得医药科技股份有限公司 400-1647117 15221909166 product02@bidepharm.com 中国 61720 58
InvivoChem中国 13549236410 sales@invivochem.cn 中国 6712 58
TargetMol中国(陶术生物) 4008200310 marketing@tsbiochem.com 中国 24131 58
湖北魏氏化学试剂股份有限公司 027-59105166 13125137732 2853863890@qq.com 中国 2940 58
嘉兴市浙嘉生物科技有限公司 0573-85609002 18157336032 zhejia01@163.com 中国 7858 58
上海健超生物科技有限公司 13621743886 13621743886 3366408901@qq.com 中国 3821 58
南京世洲生物科技有限公司 025-85560043 15850508050 cindy.huang@synzest.com 中国 12007 58
北京炎礼生物科技有限公司 18518950109 jason_gao@yl-pharminblock.com 中国 1942 58
上海杰瑞兴生物医药科技有限公司 17721492509 643638326@qq.com 中国 5347 58
湖北魏氏化学试剂股份有限公司 027-027-59102966 18717199209 2853877583@qq.com 中国 5768 58
ATK CHEMICAL COMPANY LIMITED +undefined-21-51877795 ivan@atkchemical.com 中国 32686 60
常州安奈凯医药科技有限公司 +86-0519-8359-8696 +8618018249389 sales@anikare.com 中国 8393 58
Aladdin Scientific Corporation +1-833-552-7181 sales@aladdinsci.com 美国 52927 58
Young Lively PharminBlock Co.,Ltd +undefined18600731423 jason_gao@yl-pharminblock.com 中国 1944 58
北京信达和众国际贸易有限公司 86-13810773243 sales@infoark.com.cn 中国 614 58
Shanghai Acmec Biochemical Technology Co., Ltd. +undefined18621343501 product@acmec-e.com 中国 33349 58
LEAPCHEM CO., LTD. +86-852-30606658 market18@leapchem.com 中国 43348 58
ChemExpress +86-021-58950125 info@chemexpress.com 中国 555 58
Wuhan Topule Biopharmaceutical Co., Ltd +8618327326525 masar@topule.com 中国 8474 58
Nanjing Doge Biomedical Technology Co., Ltd +86-25-58227606 +86-15305155328 sales@dogechemical.com 中国 4128 58
 

202350-68-3, PNU159682 相关搜索:

  • 化学试剂
  • 日用化学品
  • 细胞毒素
  • 细胞生物学试剂
  • 科研原药系列
  • 原料药【仅供科研】
  • 医药原料药
  • (8S,10S)-6,8,11-三羟基-8-(2-羟基乙酰基)-1-甲氧基-10-(((1S,3R,4AS,9S,9AR,10AS)-9-甲氧基-1-甲基八氢-1H-吡喃并[4',3':4,5]恶唑并[2,3-C][1,4]恶嗪-3-基)氧基)-7,8,9,10-四氢并四苯-5,12-二酮
  • (8S,10S)-6,8,11-三羟基-8-(2-羟基乙酰基)-1-甲氧基-10-(((1S,3R,4AS,9S,9AR,10AS)-9-甲氧基-1-甲基八氢-1H-吡喃并[4',3':4,5]恶唑并[2,3-C][1,4]恶嗪-3-基)氧基)-7,8,9,10-四氢并四苯-5,12-二酮
  • 化合物PNU-159682
  • 蒽环类新霉素
  • (8S,10S)-7,8,9,10-四氢-6,8,11-三羟基-8-(2-羟基乙酰基)-1-甲氧基-10-[[(1S,3R,4AS,9S,9AR,10AS)-八氢-9-甲氧基-1-甲基-1H-吡喃并[4',3':4,5]恶唑并[2,3-C][1,4]恶嗪-3-基]氧基] - 5,12-萘二酮
  • 拓扑异构酶抑制剂(PNU-159682)
  • 202350-68-3
  • (8S,10S)-6,8,11-Trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-7,8,9,10-tetrahydrotetracene-5,12-dione
  • (8S,10S)-6,8,11-Trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-7,8,9,10-tetrahydrotetracene-5,12-dione
  • inhibit,non-Hodgkin’s lymphoma,PNU159682,ADCs Toxin,PNU-159682,acute myeloid leukemia,ADC Payload,EDV nanocell,AML,Inhibitor,ADC Cytotoxin,PNU 159682,Topoisomerase,NMS249,NHL
  • 5-hydroxy-6-tert.-butyl-1,1-pentamethylene-3,3-dimethyl-indane
  • 5,12-Naphthacenedione, 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[(1S,3R,4aS,9S,9aR,10aS)-octahydro-9-methoxy-1-methyl-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl]oxy]-, (8S,10S)-
  • (8S,10S)-7,8,9,10-Tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-10-[[(1S,3R,4aS,9S,9aR,10aS)-octahydro-9-methoxy-1-methyl-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl]oxy]-5,12-naphthacenedione
  • PNU-159682 95%
  • PNU-159682 >95%
  • PNU-159682
Copyright 2016 © ChemicalBook. All rights reserved